Beam Therapeutics stock
BEAMNASDAQBeam Therapeutics Inc., HealthcareISIN US07373V1052
38Score 38 out of 100, Weak
Price and trend
39 / 100
Price history
+9.9% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 37% below its 52-week high. Largest decline in 7 years: 89% (July 2021 to April 2025).
Chart figures for advanced users
- SMA 50$25.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$27.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$20.60
- The lowest closing price of the last twelve months.
- Resistance$37.92
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Beam Therapeutics Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.49B, is number 110 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $139.74M (up 120% year on year) and a loss of $79.99M.
- MEQIRI Score 38 out of 100 (Weak): rank 558 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 466.3% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $1.04B, financial debt $243.87M.Stability 52
Weaknesses
- DilutionShare count up 112% since 2020.Capital allocation 18
- Loss-makingLoss of $107.1M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$398.24M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 41 to 38.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 120% on the prior year. Revenue turned from negative at the start of the period to positive ($139.74M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 84%, operating −275%, net −57%. Last 12 months: net −73%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 3 Nov 2026EPS reported −$1.28 (expected −$1.15)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 8.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$4.62−4.2%
- Revenue
- $38.49M−24.9%
- Earnings per share
- −$5.20−8.7%
- Revenue
- $28.23M−55.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $13.42M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Evans John M.Sale
16 Oct 2026, CEO
- Shares
- 25,000
- Price
- $23.98
- Value
- $599,595
- Evans John M.Sale
15 Oct 2026, CEO
- Shares
- 25,000
- Price
- $23.57
- Value
- $589,150
- Cavanagh Bethany JSale
1 Oct 2026, SVP, Finance and Treasurer
- Shares
- 187
- Price
- $24.41
- Value
- $4,565
Show 6 more
- Simon AmySale
27 Jul 2026, Chief Medical Officer
- Shares
- 16,667
- Price
- $25.74
- Value
- $429,037
- Simon AmySale
30 Jun 2026, Chief Medical Officer
- Shares
- 373
- Price
- $34.73
- Value
- $12,954
- Evans John M.Sale
30 Jun 2026, CEO
- Shares
- 25,000
- Price
- $34.31
- Value
- $857,685
- Evans John M.Sale
29 Jun 2026, CEO
- Shares
- 25,000
- Price
- $35.49
- Value
- $887,352
- Fmr LlcSale
26 Jun 2026, Major holder
- Shares
- 251,488
- Price
- $35.26
- Value
- $8.87M
- Fmr LlcSale
25 Jun 2026, Major holder
- Shares
- 33,372
- Price
- $35.12
- Value
- $1.17M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Beam Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BioArcticBIOA-B.ST $2.79B59
- MBX BiosciencesMBX $2.71B46
- Bavarian NordicBAVA.CO $2.7B71
- Arcus BiosciencesRCUS $2.56B30
- NewAmsterdam PharmaNAMS $2.4B35
- PharvarisPHVS $2.38B44
- Zealand PharmaZEAL.CO $2.37B59
- Replimune GroupREPL $2.31B42
ETFs that hold Beam Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.85% | 0.50% | €127.64M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.18% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.10% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.28B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.